15,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Alpha Wealth Funds LLC

Alpha Wealth Funds LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,000 shares of the company's stock, valued at approximately $425,000. Moderna comprises about 0.4% of Alpha Wealth Funds LLC's investment portfolio, making the stock its 28th largest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC increased its position in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after buying an additional 1,282,469 shares during the period. Theleme Partners LLP increased its holdings in shares of Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after acquiring an additional 72,028 shares during the period. Geode Capital Management LLC raised its position in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after purchasing an additional 171,774 shares during the last quarter. Invesco Ltd. boosted its stake in Moderna by 24.3% during the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the period. Finally, Norges Bank purchased a new position in Moderna during the 4th quarter worth $163,833,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA traded down $1.15 on Thursday, reaching $26.12. 9,843,290 shares of the company traded hands, compared to its average volume of 8,246,015. The stock has a market capitalization of $10.10 billion, a PE ratio of -2.81 and a beta of 1.86. The company's 50 day moving average is $26.11 and its 200-day moving average is $33.57. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $158.82.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period last year, the firm posted ($3.07) earnings per share. As a group, analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on MRNA. Citigroup initiated coverage on Moderna in a research note on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Evercore ISI dropped their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. UBS Group dropped their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Bank of America decreased their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.